Ginkgo Bioworks has great potential for science and investors.
AdvisorShares Psychedelics ETF, which is adding Mindset Pharma and lists Cybin as a top holding, looks like a good trip.
However, traders will need to show a lot of patience if they buy shares of the biopharmaceutical company.
Here's how traders can play the stock.
Let's take a look at Axsome Therapeutics and TG Therapeutics.
If I'm going to speculate anywhere, it might be in the iShares Nasdaq Biotechnology ETF. Here's why.
The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.
ProQR Therapeutics, Oscar Health and Hims & Hers Health appear to have promising futures.
Plus, Zscaler largely delivers for its owners with its latest results.
The charts and indicators tell us the correction is over.